[Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy]

Z Rheumatol. Sep-Oct 1992;51(5):213-21.
[Article in German]

Abstract

Due to good therapeutic results and few side-effects so-called "low-dose glucocorticoid therapy" (ldgc) with daily glucosteroid dosage below 10 mg prednisolone-equivalent has recently been recommended in managing polymyalgia rheumatica and giant cell arteritis. This fact is of important interest, since mean therapy time is often over a period of five years. An open-prospective study with 75 patients in a rheumatological unit was done in which different clinical histories were examined and glucosteroid side effects of 47 patients who had received therapy over six months were analyzed. Main side-effect shown was osteoporosis (n = 7), other known steroid-side effects were quite seldom (less than 5%). Dosage regimens and therapy monitoring criteria are proposed.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Aged, 80 and over
  • Diagnosis, Differential
  • Dose-Response Relationship, Drug
  • Female
  • Giant Cell Arteritis / diagnosis
  • Giant Cell Arteritis / drug therapy*
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / adverse effects*
  • Humans
  • Long-Term Care
  • Male
  • Middle Aged
  • Osteoporosis / chemically induced
  • Polymyalgia Rheumatica / diagnosis
  • Polymyalgia Rheumatica / drug therapy*
  • Prednisolone / administration & dosage
  • Prednisolone / adverse effects

Substances

  • Glucocorticoids
  • Prednisolone